147 related articles for article (PubMed ID: 38198042)
1. Bladder Cancer, Loss of Y Chromosome, and New Opportunities for Immunotherapy.
Mankan AK; Mankan N; de Las Heras B; Ramkissoon SH; Bodriagova O; Vidal L; Grande E; Saini KS
Adv Ther; 2024 Mar; 41(3):885-890. PubMed ID: 38198042
[TBL] [Abstract][Full Text] [Related]
2. Y chromosome loss in cancer drives growth by evasion of adaptive immunity.
Abdel-Hafiz HA; Schafer JM; Chen X; Xiao T; Gauntner TD; Li Z; Theodorescu D
Nature; 2023 Jul; 619(7970):624-631. PubMed ID: 37344596
[TBL] [Abstract][Full Text] [Related]
3. Loss of chromosome Y leads to down regulation of KDM5D and KDM6C epigenetic modifiers in clear cell renal cell carcinoma.
Arseneault M; Monlong J; Vasudev NS; Laskar RS; Safisamghabadi M; Harnden P; Egevad L; Nourbehesht N; Panichnantakul P; Holcatova I; Brisuda A; Janout V; Kollarova H; Foretova L; Navratilova M; Mates D; Jinga V; Zaridze D; Mukeria A; Jandaghi P; Brennan P; Brazma A; Tost J; Scelo G; Banks RE; Lathrop M; Bourque G; Riazalhosseini Y
Sci Rep; 2017 Mar; 7():44876. PubMed ID: 28332632
[TBL] [Abstract][Full Text] [Related]
4. ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.
Komura K; Yoshikawa Y; Shimamura T; Chakraborty G; Gerke TA; Hinohara K; Chadalavada K; Jeong SH; Armenia J; Du SY; Mazzu YZ; Taniguchi K; Ibuki N; Meyer CA; Nanjangud GJ; Inamoto T; Lee GM; Mucci LA; Azuma H; Sweeney CJ; Kantoff PW
J Clin Invest; 2018 Jul; 128(7):2979-2995. PubMed ID: 29863497
[TBL] [Abstract][Full Text] [Related]
5. Increased Expression of Y-Encoded Demethylases During Differentiation of Human Male Neural Stem Cells.
Pottmeier P; Doszyn O; Peuckert C; Jazin E
Stem Cells Dev; 2020 Dec; 29(23):1497-1509. PubMed ID: 33040644
[TBL] [Abstract][Full Text] [Related]
6. Two Splice Variants of Y Chromosome-Located Lysine-Specific Demethylase 5D Have Distinct Function in Prostate Cancer Cell Line (DU-145).
Jangravi Z; Tabar MS; Mirzaei M; Parsamatin P; Vakilian H; Alikhani M; Shabani M; Haynes PA; Goodchild AK; Gourabi H; Baharvand H; Salekdeh GH
J Proteome Res; 2015 Sep; 14(9):3492-502. PubMed ID: 26215926
[TBL] [Abstract][Full Text] [Related]
7. Lysine demethylases KDM6A and UTY: The X and Y of histone demethylation.
Gažová I; Lengeling A; Summers KM
Mol Genet Metab; 2019 May; 127(1):31-44. PubMed ID: 31097364
[TBL] [Abstract][Full Text] [Related]
8. X- and Y-Linked Chromatin-Modifying Genes as Regulators of Sex-Specific Cancer Incidence and Prognosis.
Tricarico R; Nicolas E; Hall MJ; Golemis EA
Clin Cancer Res; 2020 Nov; 26(21):5567-5578. PubMed ID: 32732223
[TBL] [Abstract][Full Text] [Related]
9. AZFa candidate gene
Vogt PH; Zimmer J; Bender U; Strowitzki T
Reprod Fertil; 2021 Apr; 2(2):151-160. PubMed ID: 35128450
[TBL] [Abstract][Full Text] [Related]
10. Y disruption, autosomal hypomethylation and poor male lung cancer survival.
Willis-Owen SAG; Domingo-Sabugo C; Starren E; Liang L; Freidin MB; Arseneault M; Zhang Y; Lu SK; Popat S; Lim E; Nicholson AG; Riazalhosseini Y; Lathrop M; Cookson WOC; Moffatt MF
Sci Rep; 2021 Jun; 11(1):12453. PubMed ID: 34127738
[TBL] [Abstract][Full Text] [Related]
11. The Divergence of Neandertal and Modern Human Y Chromosomes.
Mendez FL; Poznik GD; Castellano S; Bustamante CD
Am J Hum Genet; 2016 Apr; 98(4):728-34. PubMed ID: 27058445
[TBL] [Abstract][Full Text] [Related]
12. Target sequencing and CRISPR/Cas editing reveal simultaneous loss of UTX and UTY in urothelial bladder cancer.
Ahn J; Kim KH; Park S; Ahn YH; Kim HY; Yoon H; Lee JH; Bang D; Lee DH
Oncotarget; 2016 Sep; 7(39):63252-63260. PubMed ID: 27533081
[TBL] [Abstract][Full Text] [Related]
13. The Histone Demethylase KDM5D Drives Sex Differences in Colorectal Cancer.
Cancer Discov; 2023 Aug; 13(8):1761. PubMed ID: 37387591
[TBL] [Abstract][Full Text] [Related]
14. Copy number loss of KDM5D may be a predictive biomarker for ATR inhibitor treatment in male patients with pulmonary squamous cell carcinoma.
Ura A; Hayashi T; Komura K; Hosoya M; Takamochi K; Sato E; Saito S; Wakai S; Handa T; Saito T; Kato S; Suzuki K; Yao T;
J Pathol Clin Res; 2024 Jan; 10(1):e350. PubMed ID: 37974379
[TBL] [Abstract][Full Text] [Related]
15. Histone demethylase KDM5D upregulation drives sex differences in colon cancer.
Li J; Lan Z; Liao W; Horner JW; Xu X; Liu J; Yoshihama Y; Jiang S; Shim HS; Slotnik M; LaBella KA; Wu CJ; Dunner K; Hsu WH; Lee R; Khanduri I; Terranova C; Akdemir K; Chakravarti D; Shang X; Spring DJ; Wang YA; DePinho RA
Nature; 2023 Jul; 619(7970):632-639. PubMed ID: 37344599
[TBL] [Abstract][Full Text] [Related]
16. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
Komura K; Jeong SH; Hinohara K; Qu F; Wang X; Hiraki M; Azuma H; Lee GS; Kantoff PW; Sweeney CJ
Proc Natl Acad Sci U S A; 2016 May; 113(22):6259-64. PubMed ID: 27185910
[TBL] [Abstract][Full Text] [Related]
17. Loss of chromosome Y in regulatory T cells.
Mattisson J; Halvardson J; Davies H; Bruhn-Olszewska B; Olszewski P; Danielsson M; Bjurling J; Lindberg A; Zaghlool A; Rychlicka-Buniowska E; Dumanski JP; Forsberg LA
BMC Genomics; 2024 Mar; 25(1):243. PubMed ID: 38443832
[TBL] [Abstract][Full Text] [Related]
18. CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors.
Deng B; Park JH; Ren L; Yew PY; Kiyotani K; Antic T; O'Connor K; O'Donnell PH; Nakamura Y
Cancer Rep (Hoboken); 2018 Jun; 1(1):e1002. PubMed ID: 32729250
[TBL] [Abstract][Full Text] [Related]
19. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
Bednova O; Leyton JV
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
[TBL] [Abstract][Full Text] [Related]
20. CD8
Chen X; Xu R; He D; Zhang Y; Chen H; Zhu Y; Cheng Y; Liu R; Zhu R; Gong L; Xiao M; Wang Z; Deng L; Cao K
Oncogene; 2021 Oct; 40(43):6223-6234. PubMed ID: 34552192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
